Pancreatic ductal adenocarcinoma (PDAC) harbouring germline BRCA1-2 pathogenic variants (gBRCA1-2pv) is a distinct nosological entity. Information on second-line therapy (2LT) outcome in this setting is lacking.
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv) / Orsi, Giulia; Cavaliere, Alessandro; Tortora, Giampaolo; Lonardi, Sara; Macchini, Marina; Di Marco, Mariacristina; Giordano, Guido; Vasile, Enrico; Scartozzi, Mario; Bozzarelli, Silvia; Noventa, Silvia; Rodriquenz, Maria Grazia; Militello, Anna Maria; Rapposelli, Ilario Giovanni; Garajova, Ingrid; De Lorenzo, Stefania; Merelli, Barbara; Bittoni, Alessandro; Salvatore, Lisa; Procaccio, Letizia; Paratore, Chiara; Spallanzani, Andrea; Peretti, Umberto; Niger, Monica; Giommoni, Elisa; Bernardini, Ilaria; Tamburini, Emiliano; Bernardino, Katia; Forti, Laura; Valente, Maria Maddalena; Cascinu, Stefano; Milella, Michele; Reni, Michele. - In: BRITISH JOURNAL OF CANCER. - ISSN 0007-0920. - (2022). [10.1038/s41416-022-02086-w]
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv)
Orsi, Giulia;Cascinu, Stefano;Reni, Michele
Ultimo
2022-01-01
Abstract
Pancreatic ductal adenocarcinoma (PDAC) harbouring germline BRCA1-2 pathogenic variants (gBRCA1-2pv) is a distinct nosological entity. Information on second-line therapy (2LT) outcome in this setting is lacking.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
